medigraphic.com

2014, Number 3

<< Back Next >>

Rev Hematol Mex 2014; 15 (3)

Atypical low back pain by a solitary plasmacytoma presenting simultaneously with a psoas abscess: two different entities in a same location. A report of the first case

Alemán-Iñiguez JM, Alemán-Iñiguez PJ, Mora-Bravo F

Language: Spanish
References: 15
Page: 129-136
PDF size: 438.09 Kb.


ABSTRACT

The solitary bone plasmacytoma is the least common of the plasma cell neoplasms, most often appears in the fifth decade of life, their symptoms are related to chronic bone pain. We present the first case report in the literature of a rare coexistence of an infiltrating spinal injury by a solitary plasmacytoma with an abscess in the psoas muscle, we characterize this coincidence, that confuses the diagnosis of solitary bone plasmacytoma.


REFERENCES

  1. Guidelines Working Group of the UK Myeloma Forum (UKMF). Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol 2004;124:717-726.

  2. Weber DM. Solitary bone and extramedullary plasmacytoma. Hematology Am Soc Hematol Educ Program 2005;1:373-376.

  3. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117:4701-4705.

  4. Kilciksiz S, Karakoyun-Celik O, Yaman Agaoglu F, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J 2012;20:957-965.

  5. Li Z, Qi CF, Shin DM, Zingone A, et al. Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas. PLoS One 2010;5:107- 155.

  6. Kuzyk A, Mai S. Selected telomere length changes and aberrant three-dimensional nuclear telomere organization during fast-onset mouse plasmacytomas. Neoplasia 2012;14:344-351.

  7. McCarthy BA, Yang L, Ding J, Ren M, et al. NF-êB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors. Cancer 2012; 29:203-205.

  8. Gabler J, Wittmann J, Porstner M, Renz H, et al. Contribution of microRNA 24-3p and Erk1/2 to interleukin-6-mediated plasma cell survival. J Immunol 2013;43:3028-3027.

  9. Sobol U, Stiff P. Neurologic aspects of plasma cell disorders. Handb Clin Neurol 2014;120:1083-1099.

  10. Di Micco P, Di Micco. Up-date on solitary plasmacytoma and its main differences with multiple myeloma B. Exp Oncol 2005;27:7-12.

  11. Zuo Z, Liu WP, Tang Y, Bi CF, et al. Solitary plasmacytoma of bone: a clinicopathologic, immunohistochemical and immunoglobulin gene rearrangement study. Xue Za Zhi 2010;39:177-182.

  12. Chargari C, Vennarini S, Servois V, Bonardel G, et al. Place of modern imaging modalities for solitary plasmacytoma: toward improved primary staging and treatment monitoring. Crit Rev Oncol Hematol 2012;82:150-158.

  13. Agool A, Slart RH, Dierckx RA, Kluin PM, et al. Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma. J Nucl Med Mol Imaging 2010;37:124-130.

  14. Wilder RB, Ha CS, Cox JD, et al. Persistence of myelom aprotein for more than one year after radiotherapy is anadverse prognostic factor in solitary plasmacytoma of bone. J Nucl Med Mol Imaging 2006;10:251-256.

  15. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003;101:1715-1719.




2020     |     www.medigraphic.com